Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1

This study tests a new cell therapy called NY-ESO-1 TCR/IL-15 NK cells — natural killer immune cells that have been modified to recognize and attack a protein called NY-ESO-1, which is found in certain soft-tissue sarcomas (cancers of muscle, fat, and connective tissue). **You may be eligible if...** - You are between 16 and 80 years old and weigh at least 40 kg - You have been diagnosed with synovial sarcoma or myxoid/round cell liposarcoma with a confirmed genetic translocation, OR you have another solid tumor with NY-ESO-1 expression (for the dose escalation phase) - Your tumor tests positive for the NY-ESO-1 protein and a specific tissue type marker (HLA-A*02) - Your cancer has returned or progressed after standard treatment including chemotherapy - Your heart, lungs, liver, and kidneys are functioning adequately **You may NOT be eligible if...** - You have significant unresolved side effects from previous cancer treatment - You have active bacterial, viral, or fungal infection requiring IV treatment - You have active hepatitis B, C, or HIV with a detectable viral load - You have an active autoimmune disease (within the past 12 months) - You are pregnant or breastfeeding - You are currently receiving steroids, immunosuppressive drugs, or another anti-cancer treatment Talk to your doctor to see if this trial is right for you.